This trial is evaluating whether intra-procedural intracardiac echocardiography (ICE) probe will improve 2 primary outcomes in patients with Left Atrial Appendage Occlusion. Measurement will happen over the course of 45 days post procedure.
This trial requires 72 total participants across 2 different treatment groups
This trial involves 2 different treatments. Intra-procedural Intracardiac Echocardiography (ICE) Probe is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Recent findings of this retrospective analysis and historical review are similar, demonstrating an overall success rate of 94% with LAAs as a single or primary therapeutic modality.
Data from a recent study confirms that left atrial appendage occlusion can be cured, by a long-term low left atrial mean orifice flow, and low right atrial emptying pressure or rate.
Findings from a recent study demonstrated that left atrial appendage occlusion was not associated with the prevalence of cardiac disorders, which could be an independent cause of left atrial appendage occlusion. Left atrial appendage occlusion might be caused by local mechanical factors.
This case emphasizes that acute heart failure is a transient clinical manifestation of left atrial appendage occlusion despite the presence of a normal left heart. Left atrial appendage occlusion may rarely be a marker of serious underlying disease processes.
Left atrial appendage occlusion is a well established therapeutic method for preventing atrial fibrillation after open-heart surgery. The pericardial closure method was the easiest and convenient for the surgical procedure.
Around 1250 cases of LAAO are diagnosed in the United States each year, making it one of the most commonly performed procedures in American cardiothoracic practices.
Intra-procedural [Ipa] ICE can be performed under conscious sedation with very few risks. [Ipa]ICE can be performed at the bedside or in [Ipa]ICE off-pump coronary procedures.
The use of IntraACoT did not show to be more effective in predicting post-procedural LV function or a decrease in stroke rate compared with an intravenous (IV) saline infusion as a control for the treatment of patients undergoing a TICD procedure. There is a lack of evidence supporting the effectiveness of intra-procedural intracardiac echocardiography.
There have not been any significant breakthroughs in therapies for left atrial appendage occlusion in recent years. However, it must be acknowledged that there are numerous medications available today which are effective, safe, and inexpensive, and many patients are able to obtain and afford them. Also, there has been an improvement in the quality of left atrial appendage occlusion surgery in recent years, so that surgeons rarely get to see patients who do not want the operation anymore. It is hoped that all of these factors will help to create more effective treatments for left atrial appendage occlusion in the near future.
ICUS is associated with some common side effects in patients, including periprocedural hypotension, transient left atrial/venous dysfunction, and dyspnea. These side effects occurred in up to 6% of patients.
Left atrial appendage occlusion has been performed on a wide range of ages at both medical institutions. With each year of life, the risk for thrombosis increases and the benefits diminish as left atrial appendage occlusion is performed. At the age of 55, the risk for thrombosis remains greater than the risks at the other ages, making it the right time to consider left atrial appendage occlusion.
In this small pilot study of patients with LAAO, ICPO did not improve symptoms as assessed by SF-36. However, the number of hospital admissions decreased by 43% in patient who received ICPO.